论文部分内容阅读
盐酸阿比朵尔[1](Arbidol hydrochloride,ARB),化学名为6-溴-4-(二甲氨甲基)-5-羟基-1-甲基-2-(苯硫甲基)-1H-吲哚-3-羟酸乙酯盐酸盐-水合物,20世纪90年代由前苏联药物化学研究中心研制开发,1993年在俄罗斯首次上市,属非核苷类抗病毒药物,临床上主要用于预防和治疗甲、乙型流感和急性病毒性呼吸道感染,防止感染后并发症的发生,还具有干扰素诱导作用和免疫调节作用[2,3]。本文对ARB的国内、外研究现状进行了综述,为其进一步的研究及临床应用提供科学的理论依据。
Arbidol hydrochloride (ARB), a chemical name of 6-bromo-4- (dimethylaminomethyl) -5-hydroxy- 1-methyl-2- (phenylthiomethyl) 1H-indole-3-carboxylic acid ethyl ester hydrochloride - hydrate, developed in the 1990s by the former Soviet Union Center for Medicinal Chemistry, first listed in Russia in 1993, is a non-nucleoside antiviral drug, mainly clinically For the prevention and treatment of influenza A and B, and acute viral respiratory tract infections to prevent post-infection complications, but also has an interferon-induced and immunomodulatory effects [2,3]. This article summarizes the research status of ARB both at home and abroad, and provides a scientific theoretical basis for its further research and clinical application.